SCHEMBL884592

SCHEMBL884592

N#Cc1ccc(Nc2ccccc2CC(c2cccnc2)c2cccnc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 14/20 0.46
KCNH2 Q12809 6/20 0.46
CYP19A1 P11511 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.40
JAK2 O60674 1/20 0.36
CCNK O75909 1/20 0.35
CDK12 Q9NYV4 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
MAPK10 P53779 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884632 0.83 KCNA5 (0.49) KCNA5KCNH2TSHRSMN1; SMN2
SCHEMBL884625 0.82 KCNA5 (0.53) KCNA5KCNH2HTTMAPK10
SCHEMBL884751 0.80 KCNA5 (0.46) KCNA5KCNH2CYP19A1TSHR
SCHEMBL884872 0.80 KCNA5 (0.53) KCNA5KCNH2HPGDSMN1; SMN2
SCHEMBL2063519 0.79 HPGD (0.48) KCNA5KCNH2LMNAHPGDTSHR
SCHEMBL885079 0.77 KCNA5 (0.56) KCNA5KCNH2TSHRSMN1; SMN2
SCHEMBL884575 0.76 KCNA5 (0.52) KCNA5KCNH2TSHRSMN1; SMN2
SCHEMBL884331 0.76 KCNA5 (0.49) KCNA5KCNH2SMN1; SMN2
SCHEMBL884862 0.76 KCNA5 (0.57) KCNA5KCNH2SMN1; SMN2
SCHEMBL884842 0.75 CYP19A1 (0.48) KCNA5KCNH2CYP19A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US claimed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885CYP19A1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.